Dazoxiben
Dazoxiben is a thromboxane antagonist. It was developed by Eisai Co. and has been used in clinical trials for the treatment of asthma.
History[edit | edit source]
Dazoxiben was developed by the Japanese pharmaceutical company Eisai Co. It was primarily researched as a potential treatment for asthma, due to its ability to inhibit the action of thromboxane.
Mechanism of Action[edit | edit source]
Dazoxiben works by antagonizing the action of thromboxane A2, a compound that promotes platelet aggregation and vasoconstriction. By inhibiting the action of thromboxane A2, Dazoxiben can potentially reduce the symptoms of asthma.
Clinical Trials[edit | edit source]
Dazoxiben has been tested in clinical trials for its potential use in treating asthma. However, the results of these trials have not been conclusive, and the drug is not currently approved for use in any country.
See Also[edit | edit source]
References[edit | edit source]
Dazoxiben Resources | ||
---|---|---|
|
|
Translate to: East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski
Navigation: Wellness - Encyclopedia - Health topics - Disease Index - Drugs - World Directory - Gray's Anatomy - Keto diet - Recipes
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro) available.
Advertise on WikiMD
WikiMD is not a substitute for professional medical advice. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.Contributors: Prab R. Tumpati, MD